2c66: Difference between revisions

Revision as of 17:45, 21 February 2008

MAO INHIBITION BY RASAGILINE ANALOGUES

OverviewOverview

Monoamine oxidases A and B (MAO A and B) catalyze the degradation of neurotransmitters and represent drug targets for the treatment of neurodegenerative disorders. Rasagiline is an irreversible, MAO B-selective inhibitor that has been approved as a novel anti-Parkinson's drug. In this study, we investigate the inhibition of recombinant human MAO A and MAO B by several rasagiline analogues. Different substituents added onto the rasagiline scaffold alter the binding affinity depending on the position on the aminoindan ring and on the size of the substituent. Compounds with a hydroxyl group on either the C4 or the C6 atom inhibit both isozymes, whereas a bulkier substituent such as a carbamate is tolerated only at the C4 position. The 1.7 A crystal structure of MAO B in complex with 4-(N-methyl-N-ethyl-carbamoyloxy)-N-methyl-N-propargyl-1(R)-aminoindan shows that the binding mode is similar to that of rasagiline with the carbamate moiety occupying the entrance cavity space. 1(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B. The crystal structure of N-methyl-1(R)-aminoindan bound to MAO B shows that its aminoindan ring adopts a different orientation compared to that of rasagiline.

About this StructureAbout this Structure

2C66 is a Single protein structure of sequence from Homo sapiens with as ligand. Active as Amine oxidase (flavin-containing), with EC number 1.4.3.4 Known structural/functional Site: . Full crystallographic information is available from OCA.

ReferenceReference

Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis., Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A, J Med Chem. 2005 Dec 29;48(26):8148-54. PMID:16366596

Page seeded by OCA on Thu Feb 21 16:45:18 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 4: / Line 4: @@
 ==Overview==
-Monoamine oxidases A and B (MAO A and B) catalyze the degradation of, neurotransmitters and represent drug targets for the treatment of, neurodegenerative disorders. Rasagiline is an irreversible, MAO, B-selective inhibitor that has been approved as a novel anti-Parkinson's, drug. In this study, we investigate the inhibition of recombinant human, MAO A and MAO B by several rasagiline analogues. Different substituents, added onto the rasagiline scaffold alter the binding affinity depending on, the position on the aminoindan ring and on the size of the substituent., Compounds with a hydroxyl group on either the C4 or the C6 atom inhibit, both isozymes, whereas a bulkier substituent such as a carbamate is, tolerated only at the C4 position. The 1.7 A crystal structure of MAO B in, complex with, 4-(N-methyl-N-ethyl-carbamoyloxy)-N-methyl-N-propargyl-1(R)-aminoindan, shows that the binding mode is similar to that of rasagiline with the, carbamate moiety occupying the entrance cavity space. 1(R)-Aminoindan, the, major metabolic product of rasagiline, and its analogues reversibly, inhibit both MAO A and MAO B. The crystal structure of, N-methyl-1(R)-aminoindan bound to MAO B shows that its aminoindan ring, adopts a different orientation compared to that of rasagiline.
+Monoamine oxidases A and B (MAO A and B) catalyze the degradation of neurotransmitters and represent drug targets for the treatment of neurodegenerative disorders. Rasagiline is an irreversible, MAO B-selective inhibitor that has been approved as a novel anti-Parkinson's drug. In this study, we investigate the inhibition of recombinant human MAO A and MAO B by several rasagiline analogues. Different substituents added onto the rasagiline scaffold alter the binding affinity depending on the position on the aminoindan ring and on the size of the substituent. Compounds with a hydroxyl group on either the C4 or the C6 atom inhibit both isozymes, whereas a bulkier substituent such as a carbamate is tolerated only at the C4 position. The 1.7 A crystal structure of MAO B in complex with 4-(N-methyl-N-ethyl-carbamoyloxy)-N-methyl-N-propargyl-1(R)-aminoindan shows that the binding mode is similar to that of rasagiline with the carbamate moiety occupying the entrance cavity space. 1(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B. The crystal structure of N-methyl-1(R)-aminoindan bound to MAO B shows that its aminoindan ring adopts a different orientation compared to that of rasagiline.
 ==About this Structure==
@@ Line 15: / Line 15: @@
 [[Category: Single protein]]
 [[Category: Binda, C.]]
-[[Category: Edmondson, D.E.]]
+[[Category: Edmondson, D E.]]
 [[Category: Herzig, Y.]]
 [[Category: Hubalek, F.]]
@@ Line 34: / Line 34: @@
 [[Category: transmembrane]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb  3 10:31:57 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:45:18 2008''